

FORM NUM: 500.1.03

Academic Personnel Short Profile / Short CV

| University: | University of Nicosia |
|----------------------|-----------------------------|
| Surname: | Kyriakides |
| Name: | Theodoros |
| Rank/Position: | Professor of Neurology |
| Faculty: | Medical School |
| Department: | Basic and Clinical Sciences |
| Scientific Domain: * | Neurology |

* Field of Specialization

| Academic qualifications (list by highest qualification) | | | | | |
|--|-----------|------------------------------|------------|-------------------------------|--|
| Qualification | Year | Awarding Institution | Department | Thesis title (Optional Entry) | |
| MRCP(UK),FRCP(Lon) | 1986/2003 | Royal Colleges of Physicians | N/A | N/A | |
| MB.ChB | 1983 | Bristol University | N/A | N/A | |
| BSc (Hons) Physiology | 1981 | Bristol University | N/A | N/A | |
| | | | | | |

| Employm | Employment history in Academic Institutions/Research Centers – List by the three (3) most recent | | | | | | |
|-----------------|--|--|----------|----------------------------------|--|--|--|
| Period of emple | oyment | Employer | Location | Desition | | | |
| From | То | Employer | Eocation | Position | | | |
| 2013 | Present | University of Nicosia | Nicosia | Professor of Neurology | | | |
| 2011 | 2013 | University of Nicosia | Nicosia | Senior Lecturer | | | |
| 1992 | 2019 | Cyprus Institute of Neurology& Genetics | Nicosia | Senior Consultant Neurologist | | | |

| Ref. Number | Year | Title | Other authors | Journal and Publisher / Conference | Vol. | Pages |
|-------------|------|--|---|--|------|-------------|
| 1 | 2023 | Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy | Dardiotis E | Curr Neuropharmacol | 21 | 471- 481 |
| 2 | 2022 | Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update | THAOS investigators | Orphanet J Rare Dis. | 17 | 236 |
| 3 | 2021 | Long-term safety and efficacy of patisiran for hereditary transthyretin- mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study | David Adams , Michael Polydefkis , Alejandra González-Duarte , Jonas Wixner ,Arnt V Kristen , Hartmut H Schmidt , John L Berk , Inés Asunción Losada LópezAngela Dispenzieri , Dianna Quan , Isabel M Conceição , Michel S Slama ,Julian D Gillmore , Theodoros Kyriakides, Senda Ajroud- Driss, MárciaWaddington- Cruz , Michelle M Mezei, ViolainePlanté-ordeneuve , ShahramAttarian, Elizabeth Mauricio,Thomas H Brannagan 3rd, Mitsuharu Ueda, Emre Aldinc, Jing Jing Wang, Matthew T White , John Vest, Erhan Berber, MarianneT Sweetser , Teresa Coelho | Lancet Neurol | 1 | 49-59 |

| 4 | 2020 | The frequency of central nervous system complications in the Cypriot cohort of ATTRV30M neuropathy transplanted patients | Efthimios Dardiotis , Savanna Andreou , Athina- Maria Aloizou , Elena Panayiotou , Vasileios Siokas , Mihaela Nedea Ioannou Emmelia Vounou , Kyproula Christodoulou , George A Tanteles , Demos Michaelides | Neurol Sci | 41(5) | 1163- 1170. |
|---|------|--|---|---|-----------------------|----------------|
| 5 | 2019 | C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer's disease. | Panayiotou E, Fella E, AndreouS, Pacharalambous R, Gerasimou P, Costeas P, Angeli S, Kousiappa I, Papacostas S | PLoS One. | Dec 6;14 | (12 |
| 6 | 2019 | Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis | Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, , Merlini G, Obici L, Plante- Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M | Amyloid | Jan 24: | 1-5 |
| 7 | 2017 | Gene variants of adhesion molecules act as modifiers of disease severity in MS. | Dardiotis E, Panayiotou E, Provatas A, Christodoulou K, Hadjisavvas A, Antoniades A, Lourbopoulos A, Pantzaris M, Grigoriadis N, Hadjigeorgiou GM | Neurol Neuroimmunol Neuroinflamm. | Apr 24;4 | (4) |
| 8 | 2019 | Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin- mediated amyloidosis. | Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Obici L | Neurodegener Dis Manag. 2019. | Feb;9(1): | 5-23 |
| 9 | 2005 | Phenotypic spectrum of disorders associated with glucyl-tRNA synthetase mutations. | Sivakumar K, Puls I, Nicolson GA, Funalot B, Antonellis A, Sambuughin N, Christodoulou K, Beggs JL, | Brain | Jul 13: 128: 23 | 04-14. |

| | | | Zamba-Papanicolaou E, Ionasescu V, Dalakas MC, Green ED, Fischbeck KH, Goldfarb LG. | | | |
|----|------|---|--|---------|------|---------|
| 10 | 1995 | Mutations in the dystrophin- associated protein γ- sarcoglycan in chromosome 13 muscular dystrophy. Science, 1995; 270: 819-822. | Noguchi S, McNally E, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M,Yamamoto H, Bφnnemann C G, Gussoni E, Denton P H, Middleton L T, Hentati F, Ben Hamida M, Nonaka I, Vance J M, Kunkel L M, Ozawa E | Science | 270: | 819-822 |

| | Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) | | | | | |
|-------------|--|-------|-----------------------|-----------|--------------------|--|
| Ref. Number | Date | Торіс | International / Local | Location* | Role in Exhibition | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |
| 10 | | | | | | |

*Specify venue, geographic location etc

| | Research Projects. List the five (5) more recent and other five (5) selected (max total 10) | | | | | |
|---------------|--|---|--------------------------------------|------------------------|--|--|
| Ref. umber | Date | Title | Funded by | Project Role* | | |
| 1 | Oct 2014- Sept 2017 | A therapeutic trial of a Complement 5a receptor (C5aR) antagonist in a transgenic mouse model of Familial amyloidotic neuropathy Type I (TTRMet30Val) | Telethon | Scientific Coordinator | | |
| 2 | May 2011- April 2014 | A study of modifier genes on disease severity in Multiple sclerosis' Support period | Cyprus Research Foundation IPE | Scientific Coordinator | | |
| 3 | April 2009- Sept 2011 | A study of the role of complement C1Q in an animal model of Familial Amyloidotic neuropathy Type I | Cyprus Research Foundation IPE | Scientific Coordinator | | |
| 4 | September 2005- January 2008 | A study of modifier genes in Mitochondrial Encephalomyopathies | Cyprus Research Foundation IPE | Scientific Coordinator | | |
| 5 | January 2004 – January 2006 | Therapeutic trial of Melatonin and Trimetazidine in a Transgenic Mouse Model of Familial ALS | Telethon | Scientific Coordinator | | |
| 6 | December 2002 –June 2005 | Cyprus Study of Familial Amyloidotic neuropathy Type I | Cyprus Research Foundation IPE | Scientific Coordinator | | |
| 7 | July 2002 – June 2005 | Neuromuscular diseases in Eastern Mediterranean countries | MDA(USA) | Scientific Coordinator | | |
| 8 | November 1994 – October 1996 | Neuromuscular diseases in Eastern Mediterranean Countries | MDA(USA) | Co-Investigator | | |

| 9 | March 1996 –June 1999 | Clinical and genetic studies of Charcot- Marie-Tooth type II and recessive forms | MDA(USA) | Co-Investigator |
|----|--------------------------|--|-------------|-----------------|
| 10 | 1996-1999 | Molecular genetics of Charcot- Marie-Tooth type II | AFM, France | Co-Investigator |

*Project Role: i.e. Scientific/Project Coordinator, Research Team Member, Researcher, Assistant Researcher, other

| Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees. List the five (5) more recent (Optional Entry) | | | | | |
|---|---------------|--|--|--|--|
| Ref. Number | Period | Organization | Title of Position or Service | Key Activities | |
| 1 | 2019-current | European Academy of Neurology | Chairperson of the EAN task force on setting guidelines on how to investigate pauci/asymptomatic hyperCKemia | Provide Guidelines on the investigation of HyperCKemia | |
| 2 | 2011-2013 | European Federation of Neurological Societies | Chairperson of the EFNS task force on setting guidelines on the role of muscle biopsy in the investigation of myalgia | Provide Guidelines on the investigation of myalgia | |
| 3 | 2008-2010 | European Federation of Neurological Societies | Chairperson of the EFNS task force on setting guidelines on how to investigate pauci/asymptomatic hyperCKemia | Provide Guidelines on the investigation of HyperCKemia | |
| 4 | 1996- ongoing | Ministry of Health | Chairperson of the Cyprus National Polio Certification Committee. | Provide yearly Polio Update to WHO | |
| 5 | 2011-ongoing | Ministry of Health | Member of the Ministry of Health overseas patient sponsor committee | Approve sponsoring of patients to overseas Medical Centres | |

| Awards | Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry) | | | | | |
|----------------|--|-------|-------------|--|--|--|
| Ref. Number | Date | Title | Awarded by: | | | |
| 1 | | | | | | |
| 2 | | | | | | |
| 3 | | | | | | |
| 4 | | | | | | |
| 5 | | | | | | |
| 6 | | | | | | |
| 7 | | | | | | |
| 8 | | | | | | |
| 9 | | | | | | |
| 10 | | | | | | |

| | Other Achievements. List the five (5) more recent and other five (5) selected. (max total 10) (Optional Entry) | | | | | | |
|----------------|---|-------|-----------------|--|--|--|--|
| Ref. Number | Date | Title | Key Activities: | | | | |
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| 4 | | | | | | | |
| 5 | | | | | | | |
| 6 | | | | | | | |
| 7 | | | | | | | |
| 8 | | | | | | | |
| 9 | | | | | | | |
| 10 | | | | | | | |